Therapeutic: ocular agents
Pharmacologic: monoclonal antibodies
Treatment of neovascular (wet) macular degeneration.
Binds to vascular endothelial growth factor A (VEGF-A) receptor sites, preventing the binding of endogenous VEGF-A, resulting in ↓ endothelial proliferation, vascular leakage, and new vessel formation. Therapeutic Effects: ↓ progression of visual loss.
Adverse Reactions/Side Effects
EENT: conjunctival hemorrhage, eye pain, ↑ intraocular pressure, intraocular inflammation, vitreal floaters, endophthalmitis, retinal detachment. CV: arterial thromboembolic events.
PHYSICAL THERAPY IMPLICATIONS
Examination and Evaluation
Absorption: Intravitreal injection results in complete local bioavailability. Very low serum levels are achieved.
Metabolism and Excretion: Unknown.
Half-life: 9 days (intravitreal).
|ROUTE ||ONSET ||PEAK ||DURATION |
|intravitreal ||unknown ||after injection ||1 mo |
Contraindicated in: Hypersensitivity; Ocular/periocular infections.
Use Cautiously in: OB: Use only in pregnancy if clearly needed, use cautiously during lactation; Pedi: Safe use in children not established.
Drug-Drug: ↑ risk of serious intraocular inflammation with verteporfin.
Intravitreal (Adults): 0.5 mg (0.05 mL) once monthly; after 4 mo, injections may be given q 1–3 mo.
Solution for intravitreal injection: each vial delivers 0.5 mg (0.05 mL).